Company Profile
SeaStar Medical Stock Price, News & Catalysts
- Ticker:
- ICU
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.25 USD (+2.20%)
Close
Last updated: August 17, 2026
14.1M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ICU closed up 2.20% at $3.25. No new same-company headline was identified in the current news window.
Company overview
Organ-Failure Immunomodulation Company
SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation.
Selective Cytopheretic Device
The Selective Cytopheretic Device is incorporated into continuous renal replacement therapy circuits and is designed to reduce the activity of inflammatory immune cells.
QUELIMMUNE
QUELIMMUNE is authorized for pediatric acute kidney injury and is being adopted by children’s hospitals under a Humanitarian Device Exemption.
Adult AKI Program
The pivotal NEUTRALIZE-AKI trial is evaluating the SCD in adults with acute kidney injury requiring continuous renal replacement therapy.
Future catalysts
- Completion of enrollment in the pivotal NEUTRALIZE-AKI trial is targeted around year-end 2026.
- SeaStar plans to begin submitting PMA modules to the FDA as the adult AKI program progresses, with a potential full PMA filing in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SeaStar Medical (ICU)?
SeaStar Medical (ICU) most recently closed at 3.25 USD, a +2.20% move versus the previous session.
What is the market cap of SeaStar Medical (ICU)?
SeaStar Medical currently has a market capitalization of 14.1M USD on BioPharmSignal.
What does SeaStar Medical do?
Organ-Failure Immunomodulation Company SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation. Selective Cytopheretic Device The Selective Cytopheretic Device is incorporated into continuous renal replacement therapy circuits and is designed to reduce the activity of inflammatory immune...
On which exchange is ICU stock listed?
SeaStar Medical (ICU) is associated with NASDAQ, United States, Biopharma.
What is NEUTRALIZE-AKI?
Completion of enrollment in the pivotal NEUTRALIZE-AKI trial is targeted around year-end 2026.
Which conditions is SeaStar Medical targeting with NEUTRALIZE-AKI?
SeaStar Medical is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does SeaStar Medical describe recent progress with NEUTRALIZE-AKI?
Completion of enrollment in the pivotal NEUTRALIZE-AKI trial is targeted around year-end 2026.
What is Organ-Failure?
Organ-Failure Immunomodulation Company SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation.